Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates.

Journal of clinical microbiology - 1 Oct 2008

Mphahlele Matsie, Syre Heidi, Valvatne Håvard, Stavrum Ruth, Mannsåker Turid, Muthivhi Tshilidzi, Weyer Karin, Fourie P Bernard, Grewal Harleen M S

Abstract excerpt

Pyrazinamide is important in tuberculosis treatment, as it is bactericidal to semidormant mycobacteria not killed by other antituberculosis drugs. Pyrazinamide is also one of the cornerstone drugs retained in the treatment of multidrug-resistant tuberculosis (MDR-TB). However, due to technical difficulties, routine drug susceptibility testing of Mycobacterium tuberculosis for pyrazinamide is, in many...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amidohydrolases
Share to Antitubercular Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Fingerprinting

Share to Drug Resistance, Multiple, Bacterial

Share to Pyrazinamide

Share to South Africa

Share to Tuberculosis, Multidrug-Resistant

Share to Tuberculosis, Pulmonary

Source

Open in PubMed Open full text

Identifiers

PMID: 18753350
DOI: 10.1128/JCM.00973-08
PMCID: PMC2566105

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates.PMID 18753350Read ↗

Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia.Semantic proximity Read ↗

Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea.Semantic proximity Read ↗

Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients.Semantic proximity Read ↗

pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia.Semantic proximity Read ↗

Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.Semantic proximity Read ↗

Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium TuberculosisSemantic proximity Read ↗

Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.Semantic proximity Read ↗

Pyrazinamide resistance due to pncA gene mutation and its association with treatment outcome among tuberculosis patients of South India- A longitudinal observational study.Semantic proximity Read ↗

Pyrazinamide Susceptibility and pncA Mutation Profiles of Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Patients in Bangladesh.Semantic proximity Read ↗

Pyrazinamide resistance and pncA mutations in drug resistant Mycobacterium tuberculosis clinical isolates from Myanmar.Semantic proximity Read ↗

Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.Semantic proximity Read ↗

pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of BrazilSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.